---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-002866"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T09:46:44.248931+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics amends bylaws to enhance stockholder rights; sues Sandoz over RYZUMVI

## Summary
- Bylaws amended: written consent requirements eliminated; 20% threshold to call special meeting.
- Stockholder removal threshold reduced to simple majority; amendment threshold also reduced to simple majority.
- Filed patent infringement suit against Sandoz in NJ over ANDA for generic RYZUMVI; seeks injunction.
- Suit filed with partner FamyGen Life Sciences; Opus intends to vigorously enforce RYZUMVI IP rights.

## SEC filing metadata
- accession: 0001999371-25-002866
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000199937125002866/0001999371-25-002866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000199937125002866/ird-8k_031925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-002866
- JSON: https://secwatch.observer/filing/0001999371-25-002866.json
- Plain text: https://secwatch.observer/filing/0001999371-25-002866.txt

## Key facts
- Governance Changes
  Opus Genetics, Inc.: Amended and restated bylaws to enhance stockholder rights, including reducing thresholds for actions by written consent, calling special meetings, removing directors, and amending bylaws (effective 2025-03-19).
  - Change: bylaw amendment
  - Effective: 2025-03-19
  source text: On March 19, 2025, in connection with a periodic review of the bylaws of Opus Genetics, Inc. (the “ Company ”), the Company’s board of directors adopted amended and restated bylaws of the Company (the bylaws, as so amended and restated, the “ Amended and Restated Bylaws ”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000199937125002866/0001999371-25-002866-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.